ID: ALA3319584

Max Phase: Preclinical

Molecular Formula: C36H39N3O6

Molecular Weight: 609.72

Molecule Type: Small molecule

Representations

Canonical SMILES:  COc1ccc(C[C@H](NC(=O)[C@@H](C)NC(=O)C2=C(C)c3ccccc3C2)C(=O)N[C@@H](Cc2ccccc2)C(=O)[C@@]2(C)CO2)cc1

Standard InChI:  InChI=1S/C36H39N3O6/c1-22-28-13-9-8-12-26(28)20-29(22)34(42)37-23(2)33(41)39-31(19-25-14-16-27(44-4)17-15-25)35(43)38-30(32(40)36(3)21-45-36)18-24-10-6-5-7-11-24/h5-17,23,30-31H,18-21H2,1-4H3,(H,37,42)(H,38,43)(H,39,41)/t23-,30+,31+,36-/m1/s1

Standard InChI Key:  ZMKRLIQLFDZOLS-CIEAOGCXSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 609.72

Molecular Weight (Monoisotopic): 609.2839

AlogP: 3.34

#Rotatable Bonds: 13

Polar Surface Area: 126.13

Molecular Species: NEUTRAL

HBA: 6

HBD: 3

#RO5 Violations: 1

HBA (Lipinski): 9

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 12.01

CX Basic pKa:

CX LogP: 4.61

CX LogD: 4.61

Aromatic Rings: 3

Heavy Atoms: 45

QED Weighted: 0.26

Np Likeness Score: 0.17

References

1. de Bruin G, Huber EM, Xin BT, van Rooden EJ, Al-Ayed K, Kim KB, Kisselev AF, Driessen C, van der Stelt M, van der Marel GA, Groll M, Overkleeft HS..  (2014)  Structure-based design of β1i or β5i specific inhibitors of human immunoproteasomes.,  57  (14): [PMID:25006746] [10.1021/jm500716s]

2. Johnson HWB, Lowe E, Anderl JL, Fan A, Muchamuel T, Bowers S, Moebius DC, Kirk C, McMinn DL..  (2018)  Required Immunoproteasome Subunit Inhibition Profile for Anti-Inflammatory Efficacy and Clinical Candidate KZR-616 ((2 S,3 R)- N-(( S)-3-(Cyclopent-1-en-1-yl)-1-(( R)-2-methyloxiran-2-yl)-1-oxopropan-2-yl)-3-hydroxy-3-(4-methoxyphenyl)-2-(( S)-2-(2-morpholinoacetamido)propanamido)propenamide).,  61  (24): [PMID:30380863] [10.1021/acs.jmedchem.8b01201]

Source

Source(1):

• Scientific Literature